Research progress on stem cell therapy for aneurysmal subarachnoid hemorrhage

doi:10.3877/cma.j.issn.2095-123X.2026.03.006

Abstract

Abstract:

Aneurysmal subarachnoid hemorrhage (aSAH) is a cerebrovascular emergency associated with extremely high morbidity and mortality. Although surgical interventions and intensive care techniques have been continuously improved, the overall prognosis of patients remains poor, since early brain injury, delayed cerebral ischemia, and chronic complications severely hinder neurological rehabilitation. Stem cell therapy, owing to its multidirectional differentiation potential, potent immunomodulatory functions, and neurorestorative properties, serves as a promising novel therapeutic strategy for aSAH. This article systematically elaborates the pathological mechanisms of aSAH, systematically analyzes the therapeutic potential and mechanisms of action of stem cell therapy, reviews preliminary clinical evidence, and discusses current translational challenges and future research directions, aiming to provide a theoretical basis for basic research and clinical translation of stem cell therapy in aSAH treatment.

Key words: Aneurysmal subarachnoid hemorrhage, Stem cell therapy, Mesenchymal stem cells, Extracellular vesicles, Early brain injury, Delayed cerebral ischemia, Neurogenesis, Immunomodulation

Hongwu Qi, Jingjing Li. Research progress on stem cell therapy for aneurysmal subarachnoid hemorrhage[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2026, 16(03): 170-176.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2026.03.006

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2026/V16/I03/170

References 55

[1]	Gerhart CR, Lacy AJ, Long B, et al. High risk and low incidence diseases: aneurysmal subarachnoid hemorrhage[J]. Am J Emerg Med, 2025, 92: 138-151. DOI: 10.1016/j.ajem.2025.03.024.
[2]	Sanchez S, Miller JM, Jones MT, et al. Semiautomated hemorrhage volume quantification in aneurysmal subarachnoid hemorrhage[J]. Neurocrit Care, 2025, 42(2): 419-427. DOI: 10.1007/s12028-024-02123-x.
[3]	Lee HS, Sohn MK, Lee J, et al. Five-year functional outcomes among patients surviving aneurysmal subarachnoid hemorrhage[J]. JAMA Netw Open, 2025, 8(3): e251678. DOI: 10.1001/jamanetworkopen.2025.1678.
[4]	Ryan D, Ikramuddin S, Alexander S, et al. Three pillars of recovery after aneurysmal subarachnoid hemorrhage: a narrative review[J]. Transl Stroke Res, 2025, 16(1): 119-132. DOI: 10.1007/s12975-024-01249-6.
[5]	Culebras D, Pedrosa L, Mosteiro A, et al. Prognostic factors in aneurysmal subarachnoid hemorrhage with poor initial clinical grade[J]. Front Neurol, 2025, 16: 1536643. DOI: 10.3389/fneur.2025.1536643.
[6]	Chu L, Cao K, Jiang K, et al. Predicting early functional outcomes in aneurysmal subarachnoid hemorrhage in endovascular coiling and surgical clipping[J]. Front Neurol, 2025, 16: 1466188. DOI: 10.3389/fneur.2025.1466188.
[7]	Hammer A, Erbguth F, Hohenhaus M, et al. Neurocritical care complications and interventions influence the outcome in aneurysmal subarachnoid hemorrhage[J]. BMC Neurol, 2021, 21(1): 27. DOI: 10.1186/s12883-021-02054-6.
[8]	Llompart-Pou JA, Pérez-Bárcena J, Godoy DA. Nimodipine in aneurysmal subarachnoid hemorrhage: are old data enough to justify its current treatment regimen?[J]. Neurocrit Care, 2025, 42(2): 334-340. DOI: 10.1007/s12028-024-02182-0.
[9]	Kaplan A, Kaleem S, Huynh M. Quality improvement in the management of subarachnoid hemorrhage: current state and future directions[J]. Curr Pain Headache Rep, 2023, 27(3): 27-38. DOI: 10.1007/s11916-022-01097-9.
[10]	Vergouwen MDI, Rinkel GJE. Emergency medical management of aneurysmal subarachnoid hemorrhage[J]. Neurocrit Care, 2023, 39(1): 51-58. DOI: 10.1007/s12028-023-01757-7.
[11]	Wolf S, Mielke D, Barner C, et al. Effectiveness of lumbar cerebrospinal fluid drain among patients with aneurysmal subarachnoid hemorrhage: a randomized clinical trial[J]. JAMA Neurol, 2023, 80(8): 833-842. DOI: 10.1001/jamaneurol.2023.1792.
[12]	Tuzi S, Kranawetter B, Mielke D, et al. Systematic assessment of early brain injury severity at admission with aneurysmal subarachnoid hemorrhage[J]. Neurosurg Rev, 2024, 47(1): 838. DOI: 10.1007/s10143-024-03081-w.
[13]	Koopman I, van Wijngaarden PB, Rinkel GJE, et al. Devastating delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage[J]. Front Neurol, 2022, 13: 1016111. DOI: 10.3389/fneur.2022.1016111.
[14]	Stragier H, Vandersmissen H, Ordies S, et al. Pathophysiological mechanisms underlying early brain injury and delayed cerebral ischemia in the aftermath of aneurysmal subarachnoid hemorrhage: a comprehensive analysis[J]. Front Neurol, 2025, 16: 1587091. DOI: 10.3389/fneur.2025.1587091.
[15]	Shah VA, Gonzalez LF, Suarez JI. Therapies for delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage[J]. Neurocrit Care, 2023, 39(1): 36-50. DOI: 10.1007/s12028-023-01747-9.
[16]	Wang X, Zhang Y, Chong W, et al. Association of rebleeding and delayed cerebral ischemia with long-term mortality among 1-year survivors after aneurysmal subarachnoid hemorrhage[J]. Curr Neurovasc Res, 2022, 19(3): 282-292. DOI: 10.2174/1567202619666220822105510.
[17]	Rass V, Schoenherr E, Ianosi BA, et al. Subarachnoid hemorrhage is followed by pituitary gland volume loss: a volumetric MRI observational study[J]. Neurocrit Care, 2020, 32(2): 492-501. DOI: 10.1007/s12028-019-00764-x.
[18]	Galea I, Durnford A, Glazier J, et al. Iron deposition in the brain after aneurysmal subarachnoid hemorrhage[J]. Stroke, 2022, 53(5): 1633-1642. DOI: 10.1161/strokeaha.121.036645.
[19]	Liu H, Schwarting J, Terpolilli NA, et al. Scavenging free iron reduces arteriolar microvasospasms after experimental subarachnoid hemorrhage[J]. Stroke, 2021, 52(12): 4033-4042. DOI: 10.1161/strokeaha.120.033472.
[20]	Zhou Y, Liu Z, Yan H, et al. Different cerebrospinal fluid drainage methods and chronic hydrocephalus in patients with aneurysmal subarachnoid hemorrhage[J]. Front Neurol, 2025, 16: 1564927. DOI: 10.3389/fneur.2025.1564927.
[21]	Sutkowska K, Koper-Lenkiewicz OM, Matowicka-Karna J, et al. Impact of the transforming growth factor β (TGF-β) on brain aneurysm formation and development: a literature review[J]. Cell Mol Neurobiol, 2025, 45(1): 46. DOI: 10.1007/s10571-025-01572-y.
[22]	Abu-El-Rub E, Khaswaneh RR, Almahasneh FA, et al. Adipose tissue and bone marrow-derived mesenchymal stem cells are not really the same: investigating the differences in their immunomodulatory, migratory, and adhesive profile[J]. Biochem Genet, 2025, 63(1): 378-392. DOI: 10.1007/s10528-024-10724-6.
[23]	Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential[J]. Trends Pharmacol Sci, 2020, 41(9): 653-664. DOI: 10.1016/j.tips.2020.06.009.
[24]	Yang G, Fan X, Liu Y, et al. Immunomodulatory mechanisms and therapeutic potential of mesenchymal stem cells[J]. Stem Cell Rev Rep, 2023, 19(5): 1214-1231. DOI: 10.1007/s12015-023-10539-9.
[25]	Li C, Zhao H, Cheng L, et al. Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice[J]. Cell Biosci, 2021, 11(1): 187. DOI: 10.1186/s13578-021-00698-y.
[26]	赵小玉，李彦东，吴昊，等. 外泌体miRNA在脑胶质瘤中的诊断、治疗和预后的研究进展[J]. 中华脑科疾病与康复杂志(电子版), 2021, 11 (6): 370-374. DOI: 10.3877/cma.j.issn.2095-123X.2021.06.011.
[27]	Yamanaka S. Pluripotent stem cell-based cell therapy-promise and challenges[J]. Cell Stem Cell, 2020, 27(4): 523-531. DOI: 10.1016/j.stem.2020.09.014.
[28]	徐如祥，邱文乔. 生物组装类脑生态位促进神经再生修复展望[J]. 中华神经创伤外科电子杂志, 2022, 8(1): 1-5. DOI: 10.3877/cma.j.issn.2095-9141.2022.01.001.
[29]	Yang LY, Chen YR, Lee JE, et al. Dental pulp stem cell-derived conditioned medium alleviates subarachnoid hemorrhage-induced microcirculation impairment by promoting M2 microglia polarization and reducing astrocyte swelling[J]. Transl Stroke Res, 2023, 14(5): 688-703. DOI: 10.1007/s12975-022-01083-8.
[30]	Wan Y, Song M, Xie X, et al. BMSCs regulate astrocytes through TSG-6 to protect the blood-brain barrier after subarachnoid hemorrhage[J]. Mediators Inflamm, 2021, 2021: 5522291. DOI: 10.1155/2021/5522291.
[31]	Zhang L, Guo K, Yin S, et al. RNA-Seq reveals underlying transcriptomic mechanisms of bone marrow-derived mesenchymal stem cells in the regulation of microglia-mediated neuroinflammation after subarachnoid hemorrhage[J]. Stem Cells Dev, 2020, 29(9): 562-573. DOI: 10.1089/scd.2019.0216.
[32]	Han M, Cao Y, Guo X, et al. Mesenchymal stem cell-derived extracellular vesicles promote microglial M2 polarization after subarachnoid hemorrhage in rats and involve the AMPK/NF-κB signaling pathway[J]. Biomed Pharmacother, 2021, 133: 111048. DOI: 10.1016/j.biopha.2020.111048.
[33]	Jung H, Youn DH, Park JJ, et al. Bone-marrow-derived mesenchymal stem cells attenuate behavioral and cognitive dysfunction after subarachnoid hemorrhage via HMGB1-RAGE axis mediation[J]. Life (Basel), 2023, 13(4): 881. DOI: 10.3390/life13040881.
[34]	Xiong L, Sun L, Zhang Y, et al. Exosomes from bone marrow mesenchymal stem cells can alleviate early brain injury after subarachnoid hemorrhage through miRNA129-5p-HMGB1 pathway [J]. Stem Cells Dev, 2020, 29(4): 212-221. DOI: 10.1089/scd.2019.0206.
[35]	Zuo Y, Wang J, Liao F, et al. Inhibition of heat shock protein 90 by 17-AAG reduces inflammation via P2X7 receptor/NLRP3 inflammasome pathway and increases neurogenesis after subarachnoid hemorrhage in mice[J]. Front Mol Neurosci, 2018, 11: 401. DOI: 10.3389/fnmol.2018.00401.
[36]	Zhao H, Li Y, Chen L, et al. HucMSCs-derived miR-206-knockdown exosomes contribute to neuroprotection in subarachnoid hemorrhage induced early brain injury by targeting BDNF[J]. Neuroscience, 2019, 417: 11-23. DOI: 10.1016/j.neuroscience.2019.07.051.
[37]	Gao X, Xiong Y, Li Q, et al. Extracellular vesicle-mediated transfer of miR-21-5p from mesenchymal stromal cells to neurons alleviates early brain injury to improve cognitive function via the PTEN/Akt pathway after subarachnoid hemorrhage[J]. Cell Death Dis, 2020, 11(5): 363. DOI: 10.1038/s41419-020-2530-0.
[38]	Zhang Y, Liu J, Zhou Y, et al. miR-18a-5p shuttled by mesenchymal stem cell-derived extracellular vesicles alleviates early brain injury following subarachnoid hemorrhage through blockade of the ENC1/p62 axis[J]. Cell Tissue Res, 2023, 392(3): 671-687. DOI: 10.1007/s00441-023-03754-w.
[39]	Lang HL, Zhao YZ, Xiao RJ, et al. Small extracellular vesicles secreted by induced pluripotent stem cell-derived mesenchymal stem cells improve postoperative cognitive dysfunction in mice with diabetes[J]. Neural Regen Res, 2023: 18(3): 609-617. DOI: 10.4103/1673-5374.350205.
[40]	Chen P, Liu XY, Lin MH, et al. NeuroD1 administration ameliorated neuroinflammation and boosted neurogenesis in a mouse model of subarachnoid hemorrhage[J]. J Neuroinflammation, 2023, 20(1): 261. DOI: 10.1186/s12974-023-02949-w.
[41]	Qiu JY, Gao SQ, Chen YS, et al. OXCT1 regulates hippocampal neurogenesis and alleviates cognitive impairment via the Akt/GSK-3β/β-catenin pathway after subarachnoid hemorrhage[J]. Brain Res, 2024, 1827: 148758. DOI: 10.1016/j.brainres.2024.148758.
[42]	Li Q, Ru X, Yang Y, et al. Lipocalin-2-mediated insufficient oligodendrocyte progenitor cell remyelination for white matter injury after subarachnoid hemorrhage via SCL22A17 receptor/early growth response protein 1 signaling[J]. Neurosci Bull, 2022, 38(12): 1457-1475. DOI: 10.1007/s12264-022-00906-w.
[43]	Wang Y, Yang X, Cao Y, et al. Electroacupuncture promotes remyelination and alleviates cognitive deficit via promoting OPC differentiation in a rat model of subarachnoid hemorrhage[J]. Metab Brain Dis, 2023, 38(2): 687-698. DOI: 10.1007/s11011-022-01102-5.
[44]	Wang W, Wang Y, Gao L. Stem cells treatment for subarachnoid hemorrhage[J]. Neurologist, 2025, 30(2): 80-86. DOI: 10.1097/nrl.0000000000000589.
[45]	Kimura T, Rahmani R, Miyamoto T, et al. Vitamin D deficiency promotes intracranial aneurysm rupture[J]. J Cereb Blood Flow Metab, 2024, 44(7): 1174-1183. DOI: 10.1177/0271678x241226750.
[46]	Chen H, Chen L, Xie D, et al. Protective effects of transforming growth factor-β1 knockdown in human umbilical cord mesenchymal stem cells against subarachnoid hemorrhage in a rat model[J]. Cerebrovasc Dis, 2020, 49(1): 79-87. DOI: 10.1159/000505311.
[47]	Lai N, Wu D, Liang T, et al. Systemic exosomal miR-193b-3p delivery attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage in mice[J]. J Neuroinflammation, 2020, 17(1): 74. DOI: 10.1186/s12974-020-01745-0.
[48]	Liu Z, Wang B, Guo Q. MiR-26b-5p-modified hUB-MSCs derived exosomes attenuate early brain injury during subarachnoid hemorrhage via MAT2A-mediated the p38 MAPK/STAT3 signaling pathway[J]. Brain Res Bull, 2021, 175: 107-115. DOI: 10.1016/j.brainresbull.2021.07.014.
[49]	Brunet MC, Chen SH, Khandelwal P, et al. Intravenous stem cell therapy for high-grade aneurysmal subarachnoid hemorrhage: case report and literature review[J]. World Neurosurg, 2019, 128: 573-575. DOI: 10.1016/j.wneu.2019.04.055.
[50]	Suzuki H, Fujimoto M, Kawakita F, et al. Tenascin-C in brain injuries and edema after subarachnoid hemorrhage: findings from basic and clinical studies[J]. J Neurosci Res, 2020, 98(1): 42-56. DOI: 10.1002/jnr.24330.
[51]	Kawakita F, Kanamaru H, Asada R, et al. Potential roles of matricellular proteins in stroke[J]. Exp Neurol, 2019, 322: 113057. DOI: 10.1016/j.expneurol.2019.113057.
[52]	Xie X, Ji J, Chen X, et al. Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3[J]. Clin Transl Oncol, 2022, 24(3): 517-531. DOI: 10.1007/s12094-021-02705-7.
[53]	Gotoh S, Kawabori M, Fujimura M. Intranasal administration of stem cell-derived exosomes for central nervous system diseases[J]. Neural Regen Res, 2024, 19(6): 1249-1255. DOI: 10.4103/1673-5374.385875.
[54]	Findlay MC, Kundu M, Nelson JR, et al. Emerging treatments for subarachnoid hemorrhage[J]. CNS Neurol Disord Drug Targets, 2024, 23(11): 1345-1356. DOI: 10.2174/0118715273279212240130065713.
[55]	Wu T, He X, Su L, et al. Relationship between astrocyte damage and different levels of cerebrospinal fluid markers and prognosis in patients with subarachnoid hemorrhage[J]. Folia Neuropathol, 2024, 62(2): 147-155. DOI: 10.5114/fn.2023.132782.

Please choose a citation manager

Content to export